2024
Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain
Korman R, Hatabah D, Brown L, Harris F, Wilkinson H, Rees C, Bakshi N, Archer D, Dampier C, Morris C. Impact of arginine therapy on kyotorphin in children with sickle cell disease and vaso-occlusive pain. Blood Advances 2024, 8: 3267-3271. PMID: 38527291, PMCID: PMC11226964, DOI: 10.1182/bloodadvances.2023012209.Peer-Reviewed Original Research
2023
Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial
Rees C, Brousseau D, Cohen D, Villella A, Dampier C, Brown K, Campbell A, Chumpitazi C, Airewele G, Chang T, Denton C, Ellison A, Thompson A, Ahmad F, Bakshi N, Coleman K, Leibovich S, Leake D, Hatabah D, Wilkinson H, Robinson M, Casper T, Vichinsky E, Morris C. Sickle Cell Disease Treatment with Arginine Therapy (STArT): study protocol for a phase 3 randomized controlled trial. Trials 2023, 24: 538. PMID: 37587492, PMCID: PMC10433602, DOI: 10.1186/s13063-023-07538-z.Peer-Reviewed Original ResearchConceptsPediatric Emergency Care Applied Research NetworkSickle cell disease treatmentVaso-occlusive episodesSickle cell diseaseSTART trialArginine therapyIntravenous arginineLoading doseNormal saline three timesYoung adultsBlood Institute guidelinesParental opioid usePlacebo loading doseSubstantial illness burdenDisease-modifying therapiesPatient-reported outcomesDisease treatmentPhase 3Emergency medicine providersSaline three timesMulticenter research networkResearch NetworkIntravenous opioidsLast doseStudy drug
2022
Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial
Morris C, Bakshi N, Leake D, Gillespie S, Brown L, Harris F, Khemani K, Locke A, Rees C, Griffiths M, Reyes L, Kumari P, Shiva S, Dampier C. Impact of Arginine Therapy on Clinical Outcomes, Mitochondrial Function and Oxidative Stress in Children with Sickle Cell Disease Hospitalized with Vasoocclusive Pain Episodes: A Randomized Controlled Trial. Blood 2022, 140: 16-18. DOI: 10.1182/blood-2022-156577.Peer-Reviewed Original Research
2021
Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso‐occlusive pain: A randomized placebo‐controlled trial in progress
Reyes L, Figueroa J, Leake D, Khemani K, Kumari P, Bakshi N, Lane P, Dampier C, Morris C. Safety of intravenous arginine therapy in children with sickle cell disease hospitalized for vaso‐occlusive pain: A randomized placebo‐controlled trial in progress. American Journal Of Hematology 2021, 97: e21-e24. PMID: 34724240, PMCID: PMC8722015, DOI: 10.1002/ajh.26396.Peer-Reviewed Original Research
2019
Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress
Morris C, Figueroa J, Watt A, Khemani K, Kumari P, Barnett M, Bakshi N, Lane P, Dampier C. Safety of Intravenous Arginine Therapy in Children with Sickle Cell Disease Hospitalized for Vaso-Occlusive Pain: A Randomized Placebo-Controlled Trial in Progress. Blood 2019, 134: 995. DOI: 10.1182/blood-2019-122983.Peer-Reviewed Original ResearchVaso-occlusive pain episodesSickle cell diseaseChildren's Hospital OaklandRe-hospitalization rateAdverse eventsSerious AEsArginine bioavailabilityTreatment armsStandard dosePain scoresArginine therapyOpioid useStudy armsUnique patientsCell diseaseInpatient unitTreatment of SCDGrowth hormone stimulation testingGlobal arginine bioavailabilityIntravenous L-arginineLow arginine bioavailabilityParenteral opioid usePhase 2 RCTVaso-occlusive painPlacebo-controlled trial
2016
The role of the arginine metabolome in pain: implications for sickle cell disease
Bakshi N, Morris C. The role of the arginine metabolome in pain: implications for sickle cell disease. Journal Of Pain Research 2016, Volume 9: 167-175. PMID: 27099528, PMCID: PMC4821376, DOI: 10.2147/jpr.s55571.Peer-Reviewed Original ResearchSickle cell diseaseVaso-occlusive painArginine metabolomeArginine therapyArginine bioavailabilityLeg ulcersCell diseaseAcute vaso-occlusive painNitric oxidePhase II clinical trialGlobal arginine bioavailabilitySubset of patientsHallmark of SCDPreliminary clinical studyPromising therapeutic targetSemiessential amino acidPulmonary complicationsSCD painPulmonary hypertensionEndothelial dysfunctionPain severityPain mechanismsChronic painEarly mortalityPotent vasodilator